Background Liposomal bupivacaine is purported to extend analgesia of peripheral nerve
blocks when administered perineurally. However, evidence of the clinical effectiveness of …

The authors provide a comprehensive summary of all randomized, controlled trials (n= 76)
involving the clinical administration of liposomal bupivacaine (Exparel; Pacira …

Background/Importance Liposomal bupivacaine (LB) is a prolonged release formulation of
conventional bupivacaine designed for prolonging local or peripheral regional single …

BACKGROUND: Currently available local anesthetics approved for single-injection
peripheral nerve blocks have a maximum duration of< 24 hours. A liposomal bupivacaine …

Background Postoperative pain remains a significant issue with poor perioperative pain
management associated with an increased risk of morbidity and mortality. Liposomal …

Background Liposome bupivacaine (Exparel) is a multivesicular liposomal formulation of
bupivacaine currently approved in the United States for single-dose administration into the …

Many attempts have been made to increase the duration of local anesthetic action. One
avenue of investigation has focused on encapsulating local anesthetics within carrier …

In the multimodal approach to the management of postoperative pain, local infiltration and
regional blocks have been increasingly utilized for pain control. One of the limitations of …

Purpose Opioid analgesics, the cornerstone of effective postsurgical pain management, may
be associated with risk of opioid-related adverse drug events (ADEs) that may complicate …

Despite advances in drug technology and improvements in technology, including peripheral
nerve catheters and ultrasound, postoperative pain is still a significant problem in the clinical …